Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
merck
5
×
national
national blog main
national top stories
5
×
new york blog main
5
×
new york top stories
novartis
5
×
pfizer
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
medicare
abbvie
cancer
deals
diagnostics
president trump
administration
albert bourla
alzheimer's disease
What
bio
drug
roundup
patients
acquisitions
biggest
ceo
moves
today
advantages
albert
away
bar
becker
billions
bourla
bringing
brings
build
buy
ceos
company
company’s
crispr
daniel
dc
debut
dollars
dyne’s
eaton
executives
expect
future
gamble
gathered
gene
gilead
groups
healthcare
hearing
Language
unset
unknown
Current search:
novartis
×
pfizer
×
" new york blog main "
×
" national top stories "
×
merck
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
